
Index

A

- Amphiregulin, breast cancer
 - expression, 180
- Angiogenesis
 - biomarker, *see* Vascular endothelial growth factor
 - inhibitors
 - endostatin, 284, 285
 - paclitaxel, 283
 - thalidomide, 284
 - vascular endothelial growth factor trials
 - monoclonal antibody targeting, 279, 283, 284
 - overview, 277, 278
 - tyrosine kinase inhibitors, 279–281
 - neovascularization process in cancer, 268, 269
 - regulators, 268, 269
 - tumor growth and progression role, 270, 271
- Anthracycline-based regimens,
 - HER2/neu response studies
 - cyclophosphamide, methotrexate, 5-fluorouracil regimen
 - comparison, 143–146
 - dose response, 146, 147
 - overview, 143

B

- Biomarker, *see also specific biomarkers*
 - clinical trials
 - caveats, 5

- design, *see* Clinical trial design
- levels of evidence, 29
- criteria for useful biomarkers
 - assay reliability and
 - reproducibility, 327, 328
 - group outcomes, 326, 327
 - definition, 4
 - immunoassay, *see* Immunoassay, biomarkers
- Bone marrow tumor cells, *see* Disseminated tumor cells

C

- CA 15-3, early breast cancer recurrence detection, 258, 259
- Carcinoembryonic antigen (CEA), early breast cancer recurrence detection, 258, 259
- CBCTR, *see* Cooperative Breast Cancer Tissue Resource
- CEA, *see* Carcinoembryonic antigen
- Cell proliferation
 - assays
 - antigen-related markers, 86, 87
 - flow cytometry of nuclear DNA content and S-phase fraction, 85, 86
 - M phase, 84
 - overview, 82–84
 - proliferation index comparisons
 - clinical utility, 100–102
 - correlations, 88, 89
 - prognostic significance, 91–97
 - reproducibility and quality control, 87, 88

- risk profiles, 89, 91
 - treatment response, 97–100
 - S phase, 85, 86
 - cell cycle phases, 82, 84
 - c-erb-B2*, see HER2/neu
 - CGH, see Comparative genomic hybridization
 - Chromogenic *in situ* hybridization (CISH), *Her2* gene amplification analysis, 72, 74
 - Circulating tumor cells
 - CK-19 marker detection with reverse transcriptase–polymerase chain reaction, 221
 - detection
 - flow cytometry, 295
 - immunohistochemistry, 295, 296, 298, 299
 - immunomagnetic separation, 299, 300
 - reverse transcriptase–polymerase chain reaction, 297, 298, 299
 - immunocytochemistry, 217, 220
 - patient-specific therapy design, 314
 - prognostic value, 300, 301
 - prospects for study, 224–227, 311–313
 - selection strategies, 220, 221
 - CISH, see Chromogenic *in situ* hybridization
 - CK-19, occult metastatic cell marker
 - detection with reverse transcriptase–polymerase chain reaction, 221, 297, 298
 - Clinical trial design
 - biomarker caveats, 5
 - biomarker validation studies
 - examples of patient identification
 - node-negative patients not requiring chemotherapy, 12, 13
 - node-positive patients benefiting from specific regimens, 14, 15
 - node-positive patients not benefiting from chemotherapy, 13, 14
 - guidelines, 10–12, 19
 - phase III trials, 10, 11
 - retrospective study analysis of biomarkers, 6–10
 - CMF, see Cyclophosphamide, methotrexate, 5-fluorouracil
 - c-neu*, see HER2/neu
 - Comparative genomic hybridization (CGH), *Her2* gene amplification analysis, 75, 76
 - Cooperative Breast Cancer Tissue Resource (CBCTR)
 - array characteristics, 40, 43
 - origins, 39
 - Cross-validation, leave-one-out
 - cross-validation, 8, 9
 - Cyclophosphamide, methotrexate, 5-fluorouracil (CMF)
 - circulating *Her2/neu* extracellular domain as prediction indicator, 248
 - Her2/neu* response studies, 141–143
- ## D
- DCIS, see Ductal carcinoma *in situ*
 - Disseminated tumor cells (DTCs)
 - bone marrow tumor cell clinical significance, 214, 215, 222–224, 226, 227, 301–304, 311
 - CK-19 marker detection with reverse transcriptase–polymerase chain reaction, 221, 297, 298
 - detection in bone marrow
 - flow cytometry, 295
 - immunohistochemistry, 295, 296, 301
 - reverse transcriptase–polymerase chain reaction, 297, 298
 - tumor burden effects, 304, 305

- histopathology, 215
 - immunocytochemistry, 215–217
 - patient-specific therapy design, 314
 - prospective studies, 313
 - prospects for study, 224–227, 311–313
 - selection strategies, 220, 221
- DNA methylation, metastatic breast cancer, 222
- DNA microarray
- advantages, 58
 - biomarker discovery, 5, 6
 - breast tumor analysis
 - classification, 54, 55
 - historical perspective, 52
 - pathogenesis and progression studies, 52–54
 - prognosis and prediction, 55, 56
 - combinatorial analysis, 56, 57
 - data analysis, 51
 - DNA chips, 49, 50
 - messenger RNA correlation with protein levels, 57
 - microdissected samples, 57, 58
 - pooling of samples, 58
 - principles, 48, 49
 - prospects, 59
 - reference samples, 58
 - sample preparation, 50
- Docetaxel
- circulating Her2/neu extracellular domain as prediction indicator, 249–251
 - HER2/neu response studies, 147–149
- DTCs, *see* Disseminated tumor cells
- Ductal carcinoma *in situ* (DCIS)
- epidermal growth factor receptor expression, 183
 - lymph node occult metastasis, 309–311
- E**
- EGF, *see* Epidermal growth factor
- EGFR, *see* Epidermal growth factor receptor
- ELISA, *see* Enzyme-linked immunosorbent assay
- Endostatin, angiogenesis inhibition, 284, 285
- Enzyme-linked immunosorbent assay (ELISA)
- Her2/neu extracellular domain, 239, 240
 - plasminogen activator inhibitor-1, 120, 121
 - principles, 19, 20
 - urokinase plasminogen activator, 120, 121
- Epidermal growth factor (EGF)
- breast cancer expression, 179
 - structure, 178
 - transforming growth factor- α homology, 179
- Epidermal growth factor receptor (EGFR)
- breast cancer expression, 181, 182
 - breast development role, 182
 - drug resistance role, 184
 - ductal carcinoma *in situ* expression, 183
 - EGFR-2, *see* HER2/neu
 - estrogen effects on expression, 185
 - family members, 181
 - ligands, 179–181
 - signaling, 160, 181, 182, 184
 - tyrosine kinase inhibitor targeting, 183
- erb-B2, *see* HER2/neu
- F**
- FISH, *see* Fluorescence *in situ* hybridization
- Flow cytometry
- nuclear DNA content and S-phase fraction
 - overview, 85, 86
 - proliferation index comparisons, 87–89, 91–93, 97–102

- occult metastasis detection, 295
- Fluorescence *in situ* hybridization (FISH), *Her2* gene amplification analysis
- advantages, 68–70
 - limitations, 72, 74
 - optimization for archived specimens, 72, 73
 - reproducibility, 71, 72
 - trastuzumab response studies, 169, 170, 173
- G**
- Gene amplification
- breast cancer amplified genes, 66
 - Her2* amplification
 - amplicon gene types, 67
 - chromogenic *in situ* hybridization, 72, 74
 - clinical significance, 67
 - comparative genomic hybridization, 75, 76
 - fluorescence *in situ* hybridization
 - advantages, 68–70
 - limitations, 72, 74
 - optimization for archived specimens, 72, 73
 - reproducibility, 71, 72
 - immunohistochemistry, 68–70
 - metastasis samples, 67, 68
 - real-time reverse transcriptase polymerase chain reaction, 74, 75
 - trastuzumab response monitoring, 68–70
- Gene expression profiling, *see* DNA microarray
- Genomics, breast cancer treatment prospects, 328
- H**
- HER2/neu
- activation and signaling, 160, 237, 238
 - circulating extracellular domain
 - assays, 239, 240
 - early recurrence detection, 258, 259
 - prevalence in breast cancer, 240–242
 - prognostic value, 242–245
 - prospects for study, 259
 - shedding, 238
 - treatment response prediction
 - chemotherapy, 248–251
 - hormone modulation therapy, 246, 247
 - metastatic breast cancer, 252, 256–258
 - trastuzumab therapy, 251, 252
 - estrogen effects on expression, 185
 - function, 130
 - gene amplification
 - amplicon gene types, 67
 - chromogenic *in situ* hybridization, 72, 74
 - clinical significance, 67
 - comparative genomic hybridization, 75, 76
 - fluorescence *in situ* hybridization
 - advantages, 68–70
 - limitations, 72, 74
 - optimization for archived specimens, 72, 73
 - reproducibility, 71, 72
 - immunohistochemistry, 68–70
 - metastasis samples, 67, 68
 - real-time reverse transcriptase polymerase chain reaction, 74, 75
 - trastuzumab response monitoring, 68–70
 - gene locus, 236
 - structure, 130, 160, 236, 237
 - therapeutic targeting in conjunction with epidermal growth factor receptor, 185, 186

- therapeutic targeting, *see*
Trastuzumab
- treatment response monitoring in
breast cancer
- chemotherapy response
- anthracycline-based regi-
mens, 143–147
 - clinical application, 149, 150
 - cyclophosphamide,
methotrexate,
5-fluorouracil therapy,
141–143
 - preclinical data, 141
 - taxane-based regimens,
147–149
- clinical recommendations, 151,
152
- controversies, 130, 131
- endocrine manipulation response
- adjuvant chemotherapy
studies, 138–140
 - drugs, 132, 133
 - metastatic breast cancer,
133–135, 138
 - preclinical data, 133
 - study limitations, 140
- level of evidence studies, 131
- study design, 131, 132
- trastuzumab response, 150, 151
- Herceptin[®], *see* Trastuzumab
- Heregulins, breast cancer expression,
180, 181
- I**
- IHC, *see* Immunohistochemistry
- Immunoassay, biomarkers
- accuracy
 - definition, 23
 - high-dose hook effect, 24
 - interferences, 24
 - linearity, 23
 - recovery, 23, 24
- ideal criteria, 18
- interpretation, 26
- minimal consistency criteria, 26
- normalization of results, 28
- platforms, 19, 20
- precision, 25, 26
- quality control
- daily performance monitoring,
27, 28
 - external quality assessment, 28, 29
 - external quality control, 27, 28
 - internal quality control, 27
 - overview, 26, 27
 - samples, 27
- sampling bias and tissue processing,
21, 22
- sensitivity, 25
- specificity, 24, 25
- standards and calibration, 22, 23
- variability of results, 20, 21
- Immunohistochemistry (IHC)
- HER2/neu
- antigen expression, 162, 163,
168, 169
 - gene amplification analysis,
68–70
- occult metastasis detection
- bone marrow tumor cells, 215–217,
295, 296, 301
 - lymph node metastasis, 295,
296, 306, 307
 - peripheral blood, 217, 220, 295,
296, 298, 299
- p53
- mutation effects on expression,
195
 - standardization, 195, 196
- Immunomagnetic separation, occult
metastasis detection in peripheral
blood, 299, 300
- K**
- Ki-67 proliferating cell marker, 86, 87

L

Leave-one-out cross-validation (LOOCV), accuracy prediction, 8, 9

Letrozole, circulating Her2/neu extracellular domain as prediction indicator, 246, 247

LOOCV, *see* Leave-one-out cross-validation

Lymph node metastasis
clinical significance in breast cancer, 214, 294, 307–311

detection

- flow cytometry, 295
- histological review, 305, 306
- immunohistochemistry, 295, 296, 306, 307
- limitations, 305
- reverse transcriptase–polymerase chain reaction, 297, 298, 307

ductal carcinoma *in situ*, 309–311
patient-specific therapy design, 314
prospective studies, 313
prospects for study, 311–313
sentinel lymph nodes, 308, 309

M

MAI, *see* Mitotic activity index

Metastasis

circulating Her2/neu extracellular domain as treatment prediction indicator
Herceptin, 257, 258
hormone or chemotherapy, 252, 256

DNA methylation, 222

Her2/neu

- gene amplification, 67, 68
- endocrine manipulation response studies, 133–135, 138

occult metastatic cells, *see* Circulating tumor cells; Disseminated tumor cells; Lymph node metastasis

vascular endothelial growth factor expression, 271

Microarray, *see* DNA microarray; Tissue microarray

Mitotic activity index (MAI)
determination, 84

proliferation index comparisons, 87–89, 91–93, 97–102

N

National Surgical Adjuvant Breast and Bowel Project (NSABP), tissue array resources, 43

Neu, *see* HER2/neu

NSABP, *see* National Surgical Adjuvant Breast and Bowel Project

O

Occult metastasis, *see* Circulating tumor cells; Disseminated tumor cells; Lymph node metastasis

P

p53

breast cancer

gene mutations

- overexpression correlation, 195
- sequencing, 196, 197
- types and clinical relevance, 197, 198

prognostic value studies, 194, 204, 205

prospects for study, 204, 206

treatment response studies

- biological rationale, 198, 201
- limitations, 194

- p53-independent drugs, 201
 - study design, 202, 203
 - functions, 194, 195, 204
 - immunohistochemistry
 - mutation effects on expression, 195
 - standardization, 195, 196
 - single-stranded conformational polymorphism studies, 196
 - Paclitaxel
 - angiogenesis inhibition, 283
 - circulating Her2/neu extracellular domain as prediction indicator, 249–251
 - HER2/neu response studies, 147–149
 - p53 gene mutation effects, 201
 - PAI-1, *see* Plasminogen activator inhibitor-1
 - Peripheral blood tumor cells, *see* Circulating tumor cells
 - Pharmacogenomics, breast cancer treatment prospects, 328
 - Plasminogen activator inhibitor-1 (PAI-1)
 - breast cancer expression
 - cell types and distribution in tumors, 114, 115
 - modulators, 114, 115
 - prognostic value, 118–120
 - treatment response prediction, 121, 122
 - tumor grade effects, 114
 - enzyme-linked immunosorbent assay, 120, 121
 - functions, 113, 114
 - protein–protein interactions, 113
 - structure, 113
 - Polymerase chain reaction, *see* Reverse transcriptase–polymerase chain reaction
 - Proliferative activity, *see* Cell proliferation
 - Proteomics, breast cancer treatment prospects, 328
- Q**
- QC, *see* Quality control
 - Quality control (QC)
 - immunoassays for biomarkers
 - daily performance monitoring, 27, 28
 - external quality assessment, 28, 29
 - external quality control, 27, 28
 - internal quality control, 27
 - overview, 26, 27
 - samples, 27
 - proliferation indices, 87, 88
- R**
- Reverse transcriptase–polymerase chain reaction (RT-PCR)
 - Her2* gene amplification analysis with real-time reverse transcriptase polymerase chain reaction, 74, 75
 - occult metastatic cell marker detection with reverse transcriptase–polymerase chain reaction
 - bone marrow tumor cells, 297, 298
 - lymph node metastasis, 297, 298, 307
 - overview, 221
 - peripheral blood tumor cells, 297, 298, 299
 - RT-PCR, *see* Reverse transcriptase–polymerase chain reaction
- S**
- Single-stranded conformational polymorphism (SSCP), p53 studies, 196

SSCP, *see* Single-stranded conformational polymorphism

T

Tamoxifen

circulating Her2/neu extracellular domain as prediction indicator, 246, 247

HER2/neu response studies

adjuvant chemotherapy studies, 138–140
metastatic breast cancer, 133–135, 138

preclinical data, 133
study limitations, 140

transforming growth factor- α inhibition, 179

Taxanes, *see* Docetaxel; Paclitaxel

TGF- α , *see* Transforming growth factor- α

Thalidomide, angiogenesis inhibition, 284

Thymidine labeling index (TLI)

determination, 85
proliferation index comparisons, 87–89, 91–93, 97–102

Tissue microarray (TMA)

advantages, 32
analysis systems, 37, 38

applications

amplicon survey, 39
clinical laboratory, 37, 39

approaches, 33, 34

array sources

commercial sources, 40–42
Cooperative Breast Cancer Tissue Resource, 39, 40, 43
National Surgical Adjuvant Breast and Bowel Project, 43

arrayers

Advanced Tissue Arrayer, 34

Beecher Instruments

Automated Arrayer ATA-27, 34, 35

manual arrayer, 34

core numbers per case, 35

donor blocks

standard operating procedure for array construction, 35, 36
submission refusal in multicenter trials, 36, 37

historical perspective, 32, 33

limitations, 39

prospects, 39, 40

TKIs, *see* Tyrosine kinase inhibitors

TLI, *see* Thymidine labeling index

TMA, *see* Tissue microarray

Transforming growth factor- α (TGF- α)

breast cancer expression, 179, 180
epidermal growth factor homology, 179

tamoxifen inhibition, 179

Trastuzumab

circulating Her2/neu extracellular domain as prediction indicator, 251, 252

development

antibody screening, 161, 162
antigen, 161
clinical trials, 163–168
humanization, 164

immunohistochemistry assay for antigen expression, 162, 163, 168, 169

fluorescence *in situ* hybridization studies of response, 169, 170, 173

Her2 gene amplification studies, 68–70

HER2/neu response studies, 150, 151

history of development, 161

mechanism of action, 67, 68, 183, 238

prospects for study, 173

Tyrosine kinase inhibitors (TKIs)
epidermal growth factor receptor
targeting, 183
vascular endothelial growth factor
receptor targeting, 279–281

U

uPA, *see* Urokinase plasminogen
activator
Urokinase plasminogen activator (uPA)
breast cancer expression
cell types and distribution in
tumors, 114, 115
modulators, 114, 115
prognostic value, 116–118
treatment response prediction,
121, 122
tumor grade effects, 114
enzyme-linked immunosorbent
assay, 120, 121
function, 112, 113
inhibitor, *see* Plasminogen activator
inhibitor-1
metastasis role, 112
receptor binding, 113
structure, 112
therapeutic targeting, 123

V

Vascular endothelial growth factor
(VEGF)

angiogenesis role, 268–270
cancer biomarker validation, 271, 272
circulating biomarker studies
endostatin level correlation, 282
individual variability, 277
inhibition trials
monoclonal antibody
targeting, 279, 283, 284
overview, 277, 278
tyrosine kinase inhibitors,
279–281
measurement variability, 273, 277
prognostic–predictive value,
281–285
prospects for study, 285, 286
sample collection, 274–276
serum versus plasma levels,
281, 282
expression regulation, 271
isoforms, 270, 271
metastasis expression, 271
receptors, 270, 271
VEGF, *see* Vascular endothelial growth
factor

W

Western blot, Her2/neu extracellular
domain, 239